Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers
Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ND-340 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 17, 2020
Lead Product(s) : Gabapentin
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Taichung Veterans General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Carbatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuropathy.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 28, 2014
Lead Product(s) : Gabapentin
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Taichung Veterans General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ND-420 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Esophageal Squamous Cell Carcinoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2013
Lead Product(s) : Oxaliplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxaliplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Head and Neck Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 10, 2011
Lead Product(s) : Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mirtazapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Buddhist Tzu Chi General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Smilon is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2010
Lead Product(s) : Mirtazapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Buddhist Tzu Chi General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pravastatin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pravastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 22, 2010
Lead Product(s) : Pravastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
